BioStable Science & Engineering, Inc.
2621 Ridgepoint Drive
Suite 100
Austin
Texas
78754
United States
Tel: 512-386-1996
Fax: 512-243-8450
Website: http://biostable-s-e.com/
Email: info@biostable-s-e.com
About BioStable Science & Engineering, Inc.
BioStable Science and Engineering: is a cardiovascular device company focused on developing and commercializing proprietary valve repair technologies that provide an alternative to valve replacement for patients with aortic valve disease. The company’s HAART Aortic Repair Technologies are designed to simplify and standardize aortic valve repair, enabling surgeons to offer the recognized clinical benefits of valve repair to patients undergoing surgical correction of aortic insufficiency or aortic root aneurysm. Stable valve annuloplasty is universally recognized as the foundation of successful valve repair procedures. BioStable’s HAART Aortic Annuloplasty Devices are the first implants designed to provide rigid, three-dimensional stabilization of the complex anatomy of the aortic valve annulus. BioStable has completed extensive preclinical and clinical studies of it leading product, the HAART 300 Aortic Annuloplasty Device, and anticipates receiving CE Mark certification of this technology in 2016. To learn more about BioStable Science and Engineering, visit www.biostable-s-e.com.YEAR FOUNDED:
2008
LEADERSHIP:
CEO: John Wheeler
PRODUCTS:
All Products
8 articles about BioStable Science & Engineering, Inc.
-
BioStable Science & Engineering Initiates European Commercialization of the HAART™ 200 Aortic Annuloplasty Device
8/6/2021
BioStable Science & Engineering, Inc. announced today that the first commercial implantations of its HAART 200 Aortic Annuloplasty Device were performed on Monday, August 2 nd by Professor Marek Jasinski, Chief of Cardiac Surgery at Wroclaw Medical University of Silesia.
-
BioStable Science & Engineering Announces CE Mark Approval for the HAART 200 Aortic Annuloplasty Device
4/21/2021
BioStable Science & Engineering, Inc. (“BioStable”) announced today the company has received CE Mark approval for the HAART 200 Aortic Annuloplasty Device for use during bicuspid aortic valve repair.
-
BioStable Science & Engineering Announces Initial Closing of Series C Equity Round
2/25/2020
Rex Health Ventures and Orlando Health Ventures lead strong syndicate of new and existing investors
-
BioStable Science & Engineering Surpasses 500 Patients Treated Worldwide with the HAART Devices
5/3/2019
HAART Aortic Annuloplasty Devices Simplify and Standardize Aortic Valve Repair
-
BioStable Science & Engineering Announces The First Commercial Use Of The HAART 200 Aortic Annuloplasty Device
9/26/2017
-
BioStable Science & Engineering Announces U.S. Pilot Launch And First Commercial Use Of The HAART 300 Aortic Annuloplasty Device
6/14/2017
-
BioStable Science & Engineering Wins FDA Nod for Its HAART 300 Aortic Annuloplasty Device
3/22/2017
-
BioStable Science & Engineering Completes Direct De Novo Application To FDA For The HAART 300 Aortic Annuloplasty Device
10/11/2016